Abstract: An infusion solution composition having enhanced stability is disclosed.

Abstract: The present disclosure provides a pharmaceutical composition including biocompatible particles containing a sugar derivative, wherein the biocompatible particles contain a lactic acid-glycolic acid copolymer. The pharmaceutical composition may be used in combination with an anticancer drug.

Abstract: The present invention relates to the use of erythrulose as antimicrobial agent as well as to composition comprising said agent.

Abstract: An object is to provide a novel means for ameliorating mastitis or improving milk production. An ameliorating or therapeutic agent for mastitis that contains a biosurfactant, or a milk production promoting agent that contains a biosurfactant, is provided.

Abstract: A pharmaceutical composition comprising antioxidants and phenolic compounds. The pharmaceutical composition includes oleuropein, hydroxytyrosol (3?4?-DHPEA) and tyrosol (p-DHPEA) and flavomoids, such as, without limiting, rutin, quercetin, luteolin and apigenin. The pharmaceutical composition further includes caffeic acid. The pharmaceutical composition further includes oleocanthal (p-DHPEA-EDA). The pharmaceutical composition wherein oleuropein is present from about at least 30%, hydroxytyrosol from about at least 50%, tyrosol from at least about 25%, and oleocanthol from at least about 2%, and suitable pharmaceutical excipients.

Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

Abstract: A novel combination comprising the integrase strand transfer inhibitor, cabotegravir or a pharmaceutically acceptable salt or solvate thereof, with the nucleoside reverse transcriptase translocation inhibitor EFdA (MK-8591), or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of the HIV integrase or reverse transcriptase is beneficial, e.g., HIV.

Abstract: The invention relates to method for repairing aberrant; splicing, wherein such aberrant: splicing is caused by the presence of a natural pseudo exon, comprising blocking of either the natural cryptic 3? splice site or the natural cryptic 5? splice site of said natural pseudo exon with an antisense oligomeric compound (AON). Further, the invention comprises an antisense oligomeric compound targeting SEQ ID NO: 1 or SEQ ID NO: 171, preferably selected from the sequences of SEQ ID NO: 267-2040, sequences that are complementary to said sequences or sequences that have an identity of 80% with said sequences or the complementary sequences. The invention further envisages the use of two antisense oligomeric compounds, a first AON targeting SEQ ID NO: 1 and a second targeting AON or SEQ ID NO: 171. These AONs are specifically for use in the treatment of Pompe disease. It is an aspect of the invention that antisense therapy using the above AONs or combinations thereof is used in combination with ERT.

Abstract: The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siRNA) molecules that target a myostatin gene expressed by a subject, wherein the siRNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siRNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders or diseases or disorders that result in conditions in which muscle is adversely affected.

Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.

Abstract: The present disclosure relates to RNA interference (RNAi) reagents for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.

Abstract: Disclosed herein is a method for promoting reduction of heat stress in animals, as well as a composition for use in the disclosed method. The composition comprises a glucan, silica, mineral clay, mannan, and optionally an endoglucanohydrolase, and may be administered to an animal that is susceptible to or suffers from heat stress.

Abstract: This patent application describes a film developed from natural compounds to cover wounds, whose method of application is in the form of individual disposable packages, vials, syringes and/or others. This wound dressing provides a moist environment at the wound site allowing the occurrence of the autolytic debridement. The film incorporates bioactive agents such as acetylsalicylic acid, essential oils, plant extracts and others, which confer antibacterial, antifungal, anti-inflammatory, antioxidant and regenerative properties. The application method is also explored in order to simplify the life of patients, and to minimise pain and discomfort felt by them, during primary care treatment.

Abstract: Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Abstract: A method of detecting and quantifying bile acids from saliva from a human patient; the method involves collecting saliva from the patient and determining the bile acid levels in the saliva, using, for example, liquid chromatography with tandem mass spectrometry. The human patient may be treated with an enteric coated gastro-retentive oral dosage form in the form of a tablet of a bile acid sequestrant dispersed in a polymeric matrix.

Abstract: An object of the present invention is to provide a method for treatment or prevention of cancer, which not only exerts a great effect at low cost but also has few side effects. A combination drug containing a urinary alkalinization agent and vitamin C or a combination drug containing a urinary alkalinization agent, vitamin C and metformin for use in treatment or remission of cancer.

Abstract: A analgesic composition for topical application is provided that includes magnesium sulfate and a source of vitamin B12 in an amount effective for providing pain relief associated with peripheral neuropathy. The composition has a viscosity effective for allowing topical application of the composition to an afflicted area where the magnesium sulfate and vitamin B12 is absorbed through the dermis to the subcutaneous to provide pain relief relating to symptoms of peripheral neuropathy. The composition provides the novel benefits of being portable, easily dispensed, and provides a higher concentration of applied magnesium sulfate and vitamin B12 than the traditional dispensing method of Epsom Salt soaking solutions.

Abstract: Disclosed are vanadyl complexes of Formula 1, Formula 2, and Formula 3, wherein R1, R2, and R are defined as in the description. The pharmaceutical compositions containing these complexes and uses of the complexes for treatment of Diabetes Mellitus, such as Diabetes Mellitus Type 2, are also disclosed.

Abstract: Topical formulations for application to exposed body tissue.

Abstract: The present invention relates to hyaluronic acid-rich node and duct system (HAR-NDS)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (NDSCs), which are adult stem cells having an ability to differentiate into HAR-NDS-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from HAR-NDS, adult stem cells NDSCs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases.

Abstract: The invention relates to blood serum, preferably from umbilical cord blood, for use in the treatment of neurodegenerative pathologies in the ophthalmic field, in particular in the treatment of glaucoma, wherein said serum comprises the nerve growth factor-? (NGF-?) together with other factors, such as, for example, BDNF. The serum can also be used for the treatment of ophthalmologic pathologies whose progression is linked to the activation of neuroinflammatory processes. The invention also relates to a composition comprising said serum and one or more excipients, and/or carriers and/or preservatives acceptable for human use; said composition can for example be in the form of a collyrium. Another aspect of the invention relates to a method for preparing the serum for the use, according to the invention, from blood, preferably from umbilical cord blood.

Abstract: Disclosed are methods and compositions useful for treating patients with inflammatory, auto-immune and age related conditions. The disclosure relates to using Natural Killer cells and derivatives thereof in order to induce therapeutic benefit to patients affected by disease and conditions such as cancer, multiple sclerosis, rheumatoid arthritis, type I diabetes mellitus, thyroid autoimmune disease, psoriasis and inflammatory bowel diseases. In some embodiments the disclosure permits physiological compensation for disease conditions by reduction of inflammatory cytokine levels in plasma and of senescent peripheral blood mononuclear cells thereby prolonging the time until medical intervention may be required. In alternate embodiments the disclosure permits physiological compensation for disease conditions by reduction of inflammatory cytokine levels in plasma and reduction of senescent peripheral blood mononuclear cells following medical intervention.

Abstract: There is described herein a method for inducing Tc22 lineage T cells from a population of CD8+ T cells, the method comprising: a) providing a population of CD8+ T cells; b) activating the population of CD8+ T cells; and c) culturing or contacting the population of CD8+ T cells with IL-6.

Abstract: Disclosed herein are compositions and methods for the treatment of liver metastases in a subject. The methods include hepatic arterial infusion (HAI) of chimeric antigen receptor modified T cells (CAR-T) which are highly specific for tumor antigens such as carcinoembryonic antigen (CEA). The HAI method is optimized to maximize exposure of the modified cells to the metastatic cells while minimizing exposure to healthy cells. The methods include co-administration of a second therapeutic agent, such as IL-2.

Abstract: Disclosed herein are methods of treating a subject exhibiting a cell that expresses Wilms tumor protein 1 (WT1). The methods typically utilize anti-WT1 antigen binding units or chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

Abstract: The present disclosure relates to non-natural NKG2D receptors attached to mammalian cell surfaces wherein the non-natural receptors do not directly signal or directly activate the cell when the receptor is bound by cognate non-natural ?1-?2 domains of NKG2D ligands modified to specifically bind the non-natural NKG2D receptors. The non-natural ?1-?2 domains of NKG2D ligands may be attached to heterologous atoms or molecules including polypeptides, in some embodiments cytokines or modified cytokines, antibodies or fragments of antibodies.

Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.

Abstract: Methods for producing megakaryocytes and platelets derived from inducible pluripotent stem cells are provided. Such megakaryocytes or platelets can be genetically modified to comprise a nucleic acid molecule encoding a therapeutic agent. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.

Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

Abstract: Embodiments of the disclosure concern methods and compositions related to treatment of diabetes and/or related conditions using cell therapy. In specific embodiments, cells that lacked the ability to produce insulin are exposed to one or more particular agents that render the cells to have the ability to produce insulin, and these cells are provided to an individual in need thereof. In a specific embodiment, the agent(s) are Wnt5a, FGF7, WNT3a, HGF, THBS2, IGF1, PDPN, LIF, endocan, SERPINF1, EGF, or a combination thereof.

Abstract: Methods of selecting umbilical cord blood units for ex-vivo expansion, separation of CD133+/CD34+ positive and uncultured CD133+/CD34+ negative fractions, methods for expanding the selected CD133+/CD34+ fraction, selection of expanded populations of CD133+/CD34+ cord blood cells for transplantation to subjects in need thereof and the therapeutic use of suitable selected, ex-vivo expanded CD 133+/CD34+ and unselected CD133/CD34 negative cord blood fractions for transplantation in the clinical setting, for treatment of hematological malignancies are provided. The present invention also envisions kits comprising the expanded and unselected cord blood fractions.

Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.

Abstract: Methods and egg yolk powder containing compositions for improving skeletal muscle protein fractional synthetic rate (FSR) in mammals and inhibiting or reversing sarcopenia are provided.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Abstract: The invention relates to an agent for use in the treatment of diseases due to an imbalance of the microbiome, in particular multiple sclerosis (MS) and Parkinson's disease, in the form of a microbiome transplant to be administered to the patient to be treated, wherein the microbiome transplant being obtainable from the stool of one or several healthy subjects through extraction with an aqueous medium, concentration of the extract and packaging to obtain a transplantable concentrate.

Abstract: Method for maintaining and improving reduced kidney function and improving quality of life in patients suffering from diseases that result in reduced renal function comprising administering RENDAYL™ in combination with standard of care treatment.

Abstract: The invention relates to direct-fed microbials for use in improving reproductive performance in animals, decreasing death loss and/or off-feed events in animals, improving milk production and/or milk quality in dairy animals, and inhibiting a disease or disorder in dairy animals selected from the group consisting of milk fever, ketosis, retained placenta, metritis, pneumonia, and displaced abomasum. More particularly, the invention relates to isolated Bacillus strains 86, 300, 101, 235, 177, and 102, and strains having all of the identifying characteristics of these strains, for uses comprising the above-mentioned uses.

Abstract: Methods, uses, compositions and kits for treating steroid-resistant chronic rhinosinusitis (CRS), including refractory CRS, in a subject, or for improving or restoring the response to anti-inflammatory sinus treatment in a patient suffering from steroid-resistant CRS, are described. These methods, uses, compositions and kits are based on the sinus administration of an effective amount of probiotics, such as lactic acid bacteria (LAB), for example Lactococcus lactis bacteria.

Abstract: Methods and uses of B. longum strain ATCC-999 for the treatment or prophylaxis of infant colic are disclosed.

Abstract: The present invention relates to a composition for use as a medicament, in the form of a gel with characteristics of a reversible thermogel, based on one or more poloxamers, water and optionally excipients, and an effective amount of an active substance. Furthermore, the present invention relates to a process for the preparation of said composition and uses thereof.

Abstract: The present invention relates to a mixture of strains of Lactobacillus crispatus, which mixture comprises strains that have a different carbohydrate degradation profile, comprising at least one strain of L. crispatus that is able to degrade glycogen, and at least one strain of L. crispatus that is able to degrade lactose. Such a mixture is of use in the treatment or prevention of bacterial vaginosis, preferably to decrease recurrence of bacterial vaginosis after treatment with antibiotics.

Abstract: Provided is the use of selectively replicating oncolytic viruses in the preparation of immunostimulants for treatment of tumors and/or cancers, wherein the oncolytic viruses do not carry exogenous immunoregulatory genes.

Abstract: The present invention relates to a composition for prevention or treatment of gynecological diseases containing an extract of Sarcodon imbricatus as an active ingredient. Specifically, the extract of Sarcodon imbricatus of the present invention can be effectively used, with only one dose, for prevention or treatment of gynecological diseases by treating dysmenorrhea, reducing a menstrual period, an amount of menstruation, menstrual irregularity, and extravasated blood, and clearing the color of menstruation.

Abstract: Described herein are pharmaceutical compositions comprising one or more modulators of a cytochrome 450 enzyme (CYP450) and substituted or unsubstituted diindolylmethane. Also described herein are methods for treating one or more skin conditions by administering a combination therapy comprising substituted or unsubstituted diindolylmethane and one or more modulators of CYP450. In particular, methods are disclosed for improving bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following the combination therapy.

Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive logP. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.

Abstract: A pharmaceutical composition comprises a Quisaqualis indica extract as an active ingredient, for preventing or treating prostatic hyperplasia, and may also be used in a food composition. The Quisaqualis indica extract may be used to treat and prevent prostatic hyperplasia by exhibiting effects of a reduction in prostate weight, a reduction in DHT as a prostatic hyperplasia inducing factor, and a reduction in prostate epithelial cell hyperplasia.

Abstract: A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual by providing a composition comprising an extract of Mikania.

Abstract: The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.